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Abstract: Hematopoietic stem cell transplantation (HSCT) is the first-line immunotherapy to treat
several hematologic disorders, although it can be associated with many complications reducing the
survival rate, such as acute graft-versus-host disease (aGvHD) and infections. Given the fundamental
role of the gut microbiome (GM) for host health, it is not surprising that a suboptimal path of
GM recovery following HSCT may compromise immune homeostasis and/or increase the risk of
opportunistic infections, with an ultimate impact in terms of aGvHD onset. Traditionally, the first
nutritional approach in post-HSCT patients is parenteral nutrition (PN), which is associated with
several clinical adverse effects, supporting enteral nutrition (EN) as a preferential alternative. The
aim of the study was to evaluate the impact of EN vs. PN on the trajectory of compositional and
functional GM recovery in pediatric patients undergoing HSCT. The GM structure and short-chain
fatty acid (SCFA) production profiles were analyzed longitudinally in twenty pediatric patients
receiving HSCT—of which, ten were fed post-transplant with EN and ten with total PN. According to
our findings, we observed the prompt recovery of a structural and functional eubiotic GM layout
post-HSCT only in EN subjects, thus possibly reducing the risk of systemic infections and GvHD onset.
Keywords: enteral nutrition; parenteral nutrition; gut microbiota; short-chain fatty acids;
hematopoietic stem cell transplantation; graft-versus-host disease
1. Introduction
Hematopoietic stem cell transplantation (HSCT) is a clinical practice routinely used to treat
patients with high-risk hematopoietic malignancies and hematological and genetic diseases. The HSCT
procedure includes a conditioning regimen, treatments with chemotherapy and/or immunotherapy,
which aim to eliminate cancer cells while allowing patients to receive donor HSCs [1,2]. One of the
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most life-threating complications of these transplant procedures, which can lead to patient morbidity
and mortality, is acute graft-versus-host disease (aGvHD), characterized by the response of alloreactive
donor T cells to host organs including skin, gut, liver, lungs and central nervous system [1–3]. The gut
microbiome (GM) has been hypothesized to have a role in aGvHD onset [4–6]. In particular, several
studies have been realized in this field, indicating that the path of GM recovery following HSCT is
closely related to the risk of developing aGvHD [4,7]. Indeed, HSCT conditioning regimens, in addition
to damaging the intestinal epithelial barrier, induce the disruption of the GM structure, with the loss of
all its probiotic properties. A prolonged GM dysbiosis following HSCT has in turn been demonstrated
to expose the patient to an increased risk of innate immune system activation (i.e., alloreactive T cells)
and systemic infections, causing aGvHD development [8,9]. Conversely, the prompt recovery of a
eubiotic GM layout may provide the host with health-promoting GM-dependent ecological services
protective against the aGvHD onset, such as barrier effect and preservation of immune homeostasis [10].
These GM-dependent probiotic activities mainly rely on a balanced production of short-chain fatty acids
(SCFAs), i.e., the end-products of GM fermentation of complex non-digestible plant polysaccharides
(e.g., cellulose, resistant starch, xylans and inulin) [11–13]. Indeed, SCFAs, mainly acetate, propionate
and butyrate, have well-known health-promoting activities, which are important to mitigate the
aGvHD development risk [14], being potent anti-inflammatory and antimicrobial compounds, as well
as strengthening the epithelial barrier and regulating the host metabolic homeostasis [12–15]. Patients
who undergo HSCT are often suffering from nutritional deficiencies, with a decrease in oral food
intake, weight loss and malnutrition due to treatment side effects (e.g., nausea, vomiting, diarrhea
and oral mucositis) [16,17]. Therefore, nutritional support after the transplant, by enteral nutrition
(EN) or parenteral nutrition (PN), has become a strategic aspect to be considered in HSCT-associated
procedures. EN, also called “tube-feeding”, is the method by which food is directly delivered inside the
patient’s gastrointestinal tract, while PN is an effective strategy of delivering nutrients directly into the
bloodstream. Nowadays, it is well known that total PN, the first-line approach for HSCT patients, is
associated with different clinical adverse effects such as infections [18–20] and metabolic disorders [21],
as well as with gut mucosal atrophy [22], cell dysfunction [23], and alterations in GM composition [24].
Conversely, EN has been indicated as a possible solution to overcome all these adverse effects. Further,
we believe that EN, by feeding the GM, besides providing nutritional benefit, can also favor the
prompt recovery of a eubiotic and SCFA-producing GM layout, with ultimate benefits in terms of
aGvHD protection. For all the reasons that link GM composition and its metabolites to post-HSCT
outcomes, as well as in light of the importance of nutritional intake to maintain an “appropriate”
GM–host relationship, here, we evaluated the efficacy of EN, in comparison with the traditional PN, in
supporting the more rapid recovery of a eubiotic GM layout in pediatric patients undergoing HSCT. In
particular, we analyzed longitudinal fecal samples from twenty pediatric patients to build GM and
SCFA production trajectories from before to up to 120 days after the transplant; ten of them were fed
with EN post-HSCT, while the rest were fed with PN.
2. Materials and Methods
2.1. Subject Enrollment and Sample Collection
A total of twenty patients who underwent HSCT were enrolled for a longitudinal study on fecal
samples approved by the Ethics Committee of the Sant’Orsola-Malpighi Hospital-University of Bologna
(ref. number 19/2013/U/Tess). Written informed consent was obtained from each enrolled patient or
parent/legal guardian. Study inclusion parameters were the availability of a pre-HSCT fecal sample
and of at least two samples collected after HSCT. Patients were clustered in two groups depending on
the feeding procedure used the days immediately after the transplant—ten patients were fed by using
EN (mean age 9.3 years) and ten patients were treated with the administration of total PN (mean age
10.1 years). Information regarding the enteral mixture administered to the patients is represented in
Supplementary Table S1. Inclusion criteria for the nutritional regimen clustered children that received
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EN nutrition for more than 7 days post-HSCT in EN group and all patients who received total PN
or EN feeding for less than 7 days after the transplant in PN group. Patients in the PN group were
chosen based on matching the ones in the EN group in terms of age, source of stem cell, type of disease
and conditioning regimen. Before the transplant, all patients received trimethoprim-cotrimoxazole
once a week for the prevention of Pneumocystis jirovecii infection and anti-fungal prophylaxis was also
performed by using voriconazole or posaconazole. None of these patients were treated with antibiotic
prophylaxis or gut decontamination. For both nutritional groups, five out of ten patients developed
acute graft-versus-host disease (aGvHD) at different grades of severity (Supplementary Table S2). In
all patients, febrile neutropenia occurred, and ceftazidime was used in all of them as the first-line
antibiotic therapy. A total of 104 fecal samples were collected before HSCT and at different time points
after the transplant, up to 120 days post-HSCT (Figure 1). Samples were stored at −20 ◦C and shipped
in dry ice to the laboratory where the microbiological analysis was performed.
Figure 1. General representation of the fecal sampling for each enrolled subject. On the top of the figure
are depicted the ten patients that followed EN (enteral nutrition), while at the bottom are highlighted
the ten subjects treated with PN (parenteral nutrition). Diamonds indicate each individual fecal sample
taken pre and post-transplant. Hematopoietic stem cell transplantation (HSCT) is indicated by the
vertical line in the graph and the moment of the eventual acute graft-versus-host disease (aGvHD)
occurrence is reported with a red star. The bars below each subject’s timeline indicate the type and the
length of the nutritional regimen followed: blue bars indicate EN and red bars indicate PN.
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2.2. Microbial DNA Extraction
Total microbial DNA was extracted from 250 mg of stool sample using the repeated bead-beating
plus column method, as previously described with few modifications [25]. Briefly, all the samples
were suspended in 1 mL of lysis buffer (500 mM NaCl, 50 mM Tris-HCl, pH 8, 50 mM EDTA, and
4% sodium dodecyl sulfate) and bead-beaten three times in a FastPrep instrument (MP Biomedicals,
Irvine, CA, USA) at 5.5 movements/s for 1 min, in the presence of four 3 mm glass beads and 0.5 g of
0.1 mm zirconia beads (BioSpec Products, Bartlesville, OK, USA). After an incubation step at 95 ◦C
for 15 min, samples were centrifuged at 13,000 rpm for 5 min. Two hundred and sixty microliters of
10 M ammonium acetate was added to the supernatant, followed by a 5 min incubation in ice and
a 10 min centrifugation at 13,000 rpm. Each sample was incubated with one volume of isopropanol,
followed by an incubation in ice for 30 min. Precipitated nucleic acids were washed with 70% ethanol,
re-suspended in 100 µL of TE (10 mM Tris-HCl, 1 mM EDTA pH 8.0) buffer, and treated with 2 µL of
10 mg/mL DNase-free RNase at 37 ◦C for 15 min. DNA purification was performed using the DNeasy
Blood and Tissue Kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions. DNA
concentration and quality were evaluated using NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA).
2.3. 16S rRNA Gene Amplification and Sequencing
The V3–V4 hypervariable region of the 16S rRNA gene was amplified by using the 341F
and 785R primers with linked Illumina adapter overhang sequences, as previously described in
Klindworth et al. [26]. Fragment amplification was performed by using KAPA HiFi HotStart ReadyMix
(Roche, Basel, CH, USA), setting the thermal cycle as follows: 3 min at 95 ◦C, 25 cycles of 30 s at
95 ◦C, 30 s at 55 ◦C, and 30 s at 72 ◦C, and a final 5 min step at 72 ◦C. Library preparation followed
a first purification with a magnetic bead-based clean-up system (Agencourt AMPure XP, Beckman
Coulter, Brea, CA, USA) and a limited-cycle PCR was performed to obtain the indexed library using
Nextera technology, followed by a second AMPure XP magnetic beads clean-up step. Final libraries
were prepared by pooling all samples to an equimolar concentration of 4nM; the denaturation and
dilution to 5 pmol was carried out before performing the sequencing on an Illumina MiSeq platform
with a 2 × 250 bp paired-end protocol according to manufacturer’s instructions (Illumina, San Diego,
CA, USA). Raw sequence reads were deposited in the National Center for Biotechnology Information
Sequence Read Archive (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA592853).
2.4. Gas Chromatography-Mass Spectrometry Determination of Short-Chain Fatty Acids in Fecal Samples
When the amount of stool material was enough, an aliquot of each sample was weighted
(approximately 250 mg), for a total of 99 fecal samples, and analyzed for SCFA determination.
The analysis of acetic acid, propionic acid and butyric acid was performed as reported in several
publications [27,28]. Briefly, samples were homogenized in 10% perchloric acid and centrifuged at
15,000 rpm for 5 min at 4 ◦C. Supernatants were diluted 1:10 in water and added with D8-butyric acid
(internal standard) to 20 µg/mL. Headspace solid-phase micro extraction (HS-SPME) was carried out
by using a 75 µm CarboxenTM/polydimethylsiloxane fiber (Supelco, Sigma-Aldrich, Milan, Italy) at
70 ◦C, with a 10 min equilibration and 30 min of extraction time. Analytes were desorbed into the gas
chromatography (GC) injector and GC–mass spectrometry analysis was carried out on a TRACE GC
2000 Series (Thermo Fisher Scientific, Waltham, MA, USA) gas chromatograph, interfaced with GCQ
Plus (Thermo Fisher Scientific, Waltham, MA, USA) mass detector with ion-trap analyzer. Phenomenex
ZB-WAX (30 m × 0.25 mm ID, 0.15 µm film thickness) capillary column was used. SCFA concentration
was expressed as micromoles per gram (µmol/g) of feces. Limit of detection ranged from 4 to 68 nmol/g.
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2.5. Bioinformatics and Statistical Analysis
A mean of 8043.9 ± 3632.5 (mean ± SD) high-quality sequences per sample was obtained. Raw
sequences were processed using a pipeline that combined PANDASeq [29] and QIIME2 [30]. After
length (minimum/maximum = 250/550 bp) and quality filtering (default parameters), reads were
cleaned and binned into amplicon sequence variants (ASVs) using DADA2 [31]. The latter is a recent
method for resolving 16S rRNA gene region variants down to the level of single-nucleotide differences,
without imposing the arbitrary dissimilarity thresholds that define operational taxonomic units [32].
Taxonomic assignment was carried out by using the VSEARCH algorithm [33] and the Greengenes
database (May 2013 release). Chimeras were discarded during the analysis. Alpha-diversity was
evaluated using two different metrics: Faith’s Phylogenetic Diversity (PD whole tree) and observed
ASVs. Weighted and Unweighted UniFrac distances were used to construct Principal Coordinates
Analysis (PCoA) graphs. All statistical analyses were performed using the R software [34]. PCoA
was generated using the “vegan” [35] and “Made4” [36] packages and data separation was tested
by permutation test with pseudo-F ratios (function “Adonis” in “vegan”). To compare differences in
microbiota composition among groups and covariates at all taxonomic levels and for alpha diversity
metrics a preliminary analysis with Wilcoxon rank-sum test or Kruskal–Wallis test was carried out.
When necessary, p values were corrected for multiple comparisons using the Benjamini–Hochberg
method. A false discovery rate (FDR) ≤ 0.05 was considered as statistically significant. * p value ≤ 0.05;
** p value ≤ 0.01.
3. Results
The 16S rRNA gene sequencing and SCFA determination were performed in a total of 104 and
99 samples, respectively, for twenty pediatric patients sampled before, during and after HSCT. Patients
were divided into two groups of ten subjects depending on the type of feeding procedure received right
after the transplant, EN or PN. Clinical and transplant characteristics are summarized in Supplementary
Table S2. Samples were grouped as “pre” (i.e., samples taken before HSCT), “HSCT” (i.e., the first
samples taken after HSCT for all subjects, ranging from 8 to 30 days post-transplant), and “post”
(i.e., all other samples taken after HSCT). In order to better visualize the trajectory of GM recovery,
post-HSCT samples were further divided into three groups: “post40” (i.e., all samples taken from 31
to 40 days post-HSCT), “post60” (i.e., samples taken from 41 to 60 days post-HSCT) and “post120”
(i.e., samples taken from 61 to 120 days after the transplant) (Figure 1).
3.1. Variation in the Overall Bacterial Biodiversity in HSCT Patients during Enteral and Parenteral Feeding
The first analysis we carried out was conducted to compare the variation of GM biodiversity from
pre- to post-HSCT samples between EN and PN subjects. Different metrics were used to estimate
alpha diversity, including phylogenetic diversity and observed ASVs. Both measures indicated, for EN
and PN patients, a reduction in GM diversity from pre-HSCT to HSCT samples. However, while PN
patients maintained a low level of GM diversity also in post-HSCT samples (Wilcoxon rank-sum test;
PRE_P vs. POST_P; observed_asvs: p = 0.05; PD_whole_tree: p = 0.13), patients fed with EN showed
the post-HSCT recovery of a level of GM diversity comparable to that observed in pre-HSCT samples
(PRE_E vs. POST_E; p = 0.44; p = 0.25). These data highlight a significantly different trajectory of GM
diversity between EN and PN patients during the course of post-HSCT recovery (POST_E vs. POST_P;
p = 0.01; p = 0.23) (Figure 2A).
In order to explore the variation in the overall GM compositional structure from pre- to post-HSCT
in EN and PN patients, a Principal Coordinates Analysis (PCoA) of unweighted UniFrac distances of
the GM profiles in the whole sample set was performed. Our data revealed a different GM response
to the HSCT perturbation between PN and EN patients. In particular, while the post-HSCT samples
from the first showed a significant shift in their GM structure (permutation test with pseudo-F ratios
(Adonis); p = 0.001) that gradually moved away from the pre-HSCT composition to the one observed
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up to 120 days post-HSCT (Figure 2B), for EN, the overall GM layout did not undergo a significant
dysbiotic shift following HSCT (p = 0.063).Nutrients 2019, 11, x FOR PEER REVIEW 2 of 12 
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Figure 2. Diversity of pre- and post-HSCT samples in patients treated with enteral and parenteral
nutritional regimens. (A) Alpha diversity estimated with observed amplicon sequence variants
(ASVs, top) and Faith’s Phylogenetic Diversity (PD_whole_tree, bottom) metrics for samples taken at
the baseline (PRE), during the transplant (HSCT) and up to 120 days post-HSCT (POST) from patients
treated with enteral (E) and parenteral (P) nutrition. Subjects treated with PN (in red) showed a
significantly higher number of ASVs (Wilcoxon rank-sum test; p = 0.01). (B) Principal Coordinates
Analysis (PCoA) based on unweighted UniFrac distances between samples taken before (PRE) and
after the transplant (HSCT, up to 30 days post-HSCT; POST40, up to 40 days post-HSCT; POST60, from
41 to 60 days post-HSCT; POST120, up to 120 days post-transplant) from patients treated with EN (top)
and PN (bottom). A significant separation among groups was observed only in patients treated with
PN (permutation test with pseudo-F ratios (Adonis), p = 0.001).
3.2. Gut Microbiota Composition in Enteral and Parenteral Nutritional Regimen during the HSCT Recovery
The GM composition analysis conducted at both the phylum and family level did not highlight
any significant difference between EN and PN groups at the baseline (PRE_E vs. PRE_P), as well as
the HSCT time points (HSCT_E vs. HSCT_P). In agreement with what has been previously observed
by Biagi et al. [4], both for EN and PN patients, HSCT samples were characterized by profound
rearrangements of the GM structure, as a result of the HSCT stress (Supplementary Figure S1).
Conversely, in the post-HSCT time points, EN and PN patients showed significant differences in the
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GM compositional structure. Specifically, while in PN subjects pre- and post-HSCT samples showed
significant variations in core GM families and genera, in EN patients, the GM composition pre- and
post-HSCT did not show any significant divergence (Figure 3).Nutrients 2019, 11, x FOR PEER REVIEW 2 of 12 
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Figure 3. Differences in the gut microbiota composition between HSCT patients following enteral and
parenteral nutrition. Boxplots representing the relative abundance distribution of genera that where
significantly different between pre-HSCT, HSCT and post-HSCT time points in PN (in red) and EN
patients (in blue). * p value ≤ 0.05; ** p value ≤ 0.01; Wilcoxon rank-sum test.
In particular, in EN patients, post-HSCT, the relative abundance of Lachnospiraceae remained
stable over time, while it decreased in subjects treated with PN (POST_E vs. POST_P: p = 0.003). This
difference was accounted for by increased representation of Blautia (POST_E vs. POST_P: p = 0.036)
and Dorea (p = 0.008), both belonging to Lachnospiraceae family, in EN-fed subjects compared to PN
patients (Figure 3). A similar increase post-HSCT in EN- vs. PN-fed patients was observed in other
genera, such as Parabacteroides (p = 0.03) and Oscillospira (p = 0.03). Interestingly, Faecalibacterium
significantly decreased in post-HSCT samples, compared to the baseline, only in PN patients (Figure 3).
Finally, patients fed with EN were characterized by a post-HSCT increase in Bacteroidaceae compared to
PN patients (POST_E vs. POST_P: p = 0.009), mostly attributable to the genus Bacteroides (p = 0.008).
A significant difference was also highlighted for Streptococcus, whose relative abundance increased
post-transplant in patients fed with PN (PRE_P vs. POST-P: p = 0.03), while no difference was observed
in EN-fed subjects. Blood culture tests were performed on patients with febrile neutropenia. For EN
patients, none of them exhibited evidence of bloodstream infection (BSI). On the other hand, seven
PN-treated patients developed eleven documented BSI, mainly attributed to Staphylococcus (36.4%),
Enterococcus (18.2%) and Streptococcus (18.2%) genera and mostly identified from 5 to 30 days post-HSCT
(Supplementary Table S2).
3.3. Short-Chain Fatty Acid Production in EN and PN Patients Undergoing HSCT
We conducted a gas chromatograph-mass spectrometry (GC–MS) analysis of fecal SCFAs in HSCT
patients fed with EN and PN from the baseline (pre-HSCT) to the transplant itself (HSCT samples), up
to 120 days after transplant (post-HSCT). According to our findings, patients who received PN were
characterized by a significant decrease in SCFA levels in post-HSCT time points compared to pre-HSCT
samples (absolute amount (µmol/g) ± SEM, PRE_P vs. POST_P; 44.0 ± 6.2 vs. 16.2 ± 2.9; p = 0.006),
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while for EN subjects, the post-HSCT SCFA production levels were comparable to the baseline (PRE_E
vs. POST_E, 35.0 ± 7.4 vs. 31.9 ± 3.1; p = 0.78) (Figure 4).
Figure 4. Fecal levels of short-chain fatty acids in HSCT patients after enteral and parenteral nutritional
regimens. Boxplots showing the absolute amount distribution for short-chain fatty acids (SCFAs)
measured in µmol/g. * p value ≤ 0.05; ** p value ≤ 0.01; Wilcoxon rank-sum test.
In detail, in post-HSCT samples, EN patients were significantly enriched in butyrate (POST_E vs.
POST_P: p = 0.01), acetate (p = 0.005) and propionate (p = 0.005) compared to subjects that received
PN. Indeed, a significant decrease in all the major SCFAs, i.e., butyrate (PRE_P vs. POST_P: p = 0.01),
acetate (p = 0.009) and propionate (p = 0.08), was observed between pre- and post-HSCT samples of
PN patients (Figure 4).
4. Discussion
Although post-HSCT enteral feeding is being increasingly recommended [37–39], intravenous
nutrient intake (PN) is still the first-line nutritional approach for the patients who received HSCT
due to its compliance, but it has been associated with several clinical and microbiological adverse
effects, including infections and GM dysbiosis [18–24]. So far, the central role of the GM composition
and biodiversity in patients undergoing HSCT has been largely evaluated in several publications,
highlighting the disruption of the gut microbial mutualistic asset after the transplant (i.e., until 30 days
post-HSCT) compared to the baseline, due to all HSCT conventional treatments that can alter the GM
recovery possibilities post-HSCT [4,5,7]. Therefore, in this scenario, we explored the potential of EN in
supporting a eubiotic GM trajectory following HSCT. To this end, the GM structure of twenty pediatric
patients undergoing HSCT (ten treated with EN and ten with PN) was analyzed at the baseline, right
after the transplant and in the post-HSCT recovery. In parallel, we evaluated the GM functionality
as SCFAs production by using GC–MS. As shown in several publications [4–7,40], right after the
transplant we observed the loss of the eubiotic GM layout. However, in EN patients, we assisted
in the prompt recovery of a diverse eubiotic GM layout, minimizing the dysbiotic shifts following
the HSCT. Interestingly, Wilmanski et al. [41] recently found a connection between the eubiotic GM
structure and the host blood metabolic profile. This suggests a possible feedback of the eubiotic GM
trajectory in HSCT patients also in terms of the blood metabolome, which has been connected with
the GvHD risk [42]. At the compositional level, EN-fed subjects recovered a GM structural layout
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comparable to the one observed before the transplant starting from 30 days post-HSCT, while in
PN patients this end point was never achieved. Particularly, we identified some genera including
Faecalibacterum, Dorea, Blautia, Bacteroides, Parabacteroides and Oscillospira, the relative abundance of
which was restored in EN patients during the post-HSCT recovery. Similar findings have very recently
been observed in an adult cohort of 23 patients undergoing HSCT by Andersen et al. [43]. Interestingly,
most of the microorganisms for which we observed the restoring in EN-fed subjects are well-known
health-promoting GM bacteria capable of producing SCFAs [12,44–49]. Consistently, the fecal levels
of SCFAs, i.e., propionate, butyrate and acetate, were restored only in EN patients between 30 and
120 days post-HSCT. These findings are in line with a recent work showing increased levels of fatty
acids in the blood of adult patients receiving mainly EN support post-HSCT [50]. As a matter of fact,
intestinal decrease in SCFA levels, especially butyrate, with a loss of GM diversity and SCFA-producers,
have been associated with post-HSCT immunological complications [14]. Recently, restoring the
physiological levels of endogenous butyrate in in vitro and in vivo models by local administration has
been shown to improve intestinal junctional integrity, decrease cellular apoptosis and mitigate GvHD
severity [14]. These observations were also demonstrated in an adult cohort that received HSCT, where
the increase in the relative abundance of the SCFA-producer Blautia was associated with the reduction
in GvHD lethality and the improvement of overall patient survival [51]. In this scenario, the potential
of EN in keeping a eubiotic and SCFA-producing GM layout may have important post-HSCT clinical
implications, as highlighted by the decrease in patient aGvHD severity and the reduction in local and
systemic infections in EN compared to PN patients [unpublished observations]. Indeed, for EN subjects,
we observed no evidence of BSI, probably supporting less impairment of the intestinal epithelial barrier.
On the other hand, PN patients were found have blood culture positivity to several microorganisms
(e.g., Staphylococcus, Enterococcus and Streptococcus genera), mainly from day 5 to 30 post-HSCT, leading
to systemic infections and clinical complications. Our results regarding the clinical outcomes of EN
patients were generally in line with most of the previous studies in literature conducted on adult
cohorts post-HSCT [18–23]. However, we cannot fail to mention that other studies provide conflicting
results for what concern the clinical outcomes of EN assumption in HSCT adult patients [52,53].
In conclusion, in EN patients, we observed prompt GM structural and functional recovery already
starting from 30 days post-HSCT, featured by the restoration of health-promoting and SCFA-producing
microorganisms and the reduction in full-blown infections. Our data indicate that post-HSCT EN
promotes the achievement of GM homeostasis, also including the production of immunomodulating
metabolites, in a window frame that is strategic to educate the process of immunological reconstruction,
possibly reducing the risk of local and systemic infections and aGvHD onset.
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